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Objectives. We sought o analyze the disease-free intervals and 
calculate the freedom from atherosclerosis events in the Program 
on the Surgical Control of the Hyperlipidemias (POSCH). 
Background. The POSCIt study was a randomized, secondary 
iipid/atherosderosis intervention trial that provided strong evi- 
dence for reduction in atherosderosis progression as demon- 
strated by clinical and arteriographic end points. The 417 control 
group patients received American Heart Association phase II diet 
instruction, and the 421 intervention group patients received 
identical dietary instruction and underwent a partial ileal bypass 
operation. 
Methods. Four outcome measures were determined: 1) overall 
mortality, 2) coronary heart disease mortality, 3) coronary heart 
disease mortality and confirmed nonfatal myocardial infarcfign, 
and 4) coronary/cardiac interventions. 
Results. An overall mortality rate of 10% occurred at 6.7 years 
in the control group and 9.4 years in the intervention group, for a 
gain in disease-free interval of 2.7 years in the intervention group 
(p = 0.032). A coronary heart disease mortality rate of 8% 
occurred at %2 years in the control group and 11 years in the 
intervention group, for a gain of 3.8 years (p = 0.046). Twenty 
percent of patients demonstrated the combined end point of 
coronary heart disease mortality ancr confirmed nonfatal myocar- 
dial infarction at 5.9 years in the control group and 11.4 years in 
the intervention group, for a gain of 5.5 years (p < 0.001). 
Twenty-five percent of patients underwent either coronary artery 
bypass graft surgery, percutaneous transluminal coronary angio- 
plasty or heart ransplantation at 5.4 years in the control group 
and 12A years in the intervention group, for a gain of 7 years (p < 
0.001). 
Conclusions. The marked lipid modification achieved by partial 
ileal bypass in the POSCH trial led to demonstrable increases in 
the disease-free intervals for overall mortality, coronary heart 
disease mortality, coronary heart disease mortality and confirmed 
nonfatal myocardial infarction, and coronary intervention proce- 
dures. For the clinician and the patient, estimation of disease-free 
intervals may be more relevant han assessment ofdifferences in 
incidence rates and risk ratios. 
(J Am CoU Cardio! 1995;26:351-7) 
Analyses of the relative disease-flee intervals in the control 
and intervention groups for clinical end points in atheroscle- 
rosis intervention trials, in particular, in lipid/atherosclerosis 
intervention trials, are absent from published reports. The 
major dietary, pharmacologic, surgical and life-style interven- 
tion trials, including the Program on the Surgical Control of 
the Hyperlipidemias (POSCH) study, have not provided ata 
on disease-free intervals or differences indisease-free intervals 
between control a~d intervention groups, for overall mortality, 
coronary heart disease mortality, nonfatal myocardial infarc- 
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tion and invasive coronary artery procedures (e.g., coronary 
artery bypass graft surgery). In contrast, ininter,'ention trials in 
oncology, the findings are routinely reported as survival rates 
and disease-flee intervals. 
Why should the reporting of lipid/atherosclerosis interven- 
tion trial results be confined to analyses of incidence? Would it 
not be of interest to investigators and, possibly even more so, 
to clinicians to estimate how long after the institution of 
therapy a represeittative patient will be free from death or a 
nonfatal myocardial infarction or an invasive coronary artery 
procedure? 
The POSCH trial has provided strong affirmation of the 
lipid/atherosclerosis theory as well as strong evidence that 
marked lipid modification leads to a reduction in atherosde- 
rosis progression (1). The POSCH trial was the first study to 
test the validity of using changes observed in sequential 
coronary arteriograms as surrogate nd points for clinical 
atherosderosis events (1,2), and POSCH was the first trial to 
demonstrate hat these changes are statistically significant 
predictors of subsequent overall mortality and coronary heart 
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disease mortality (3). The POSCH results in women showed 
that marked lipid modification by partial ileal bypass reduced 
hypercholesterolemia irrespective of gender and retarded ar- 
teriographic atherosderosis progression i  women (4). These 
are compelling reasons for a reevaluation of the POSCH 
results by disease-free interval analyses. 
Methods 
POSCH overview. Detailed descriptions of the design and 
methodology of the POSCH trial (2), recruitment and enroll- 
ment of patients (5) and baseline patient characteristics (6) 
have been published elsewhere. Four clinical centers partici- 
pated in the POSCH trial: University of Minnesota, Minneap- 
olis; University of Arkansas for Medical Sciences, Little Rock; 
University of Southern California, Los Angeles; and Lankenau 
Hospital and Research Center, Philadelphia. Between Septem- 
ber 1975 and July 1983, 838 patients (78 women) were entered 
into the POSCH trial: 417 patients (32 women) were randomly 
assigned to follow the American Heart Association phase II 
diet only (control group), and 421 patients (46 women) were 
assigned to receive identical dietary instruction plus partial 
ileal bypass (intervention group). All patients taking hypocho- 
lesterolemic drugs were asked to discontinue these medica- 
tions at least 6 weeks before the baseline plasma lipid mea- 
surements, and all patients were discouraged from resuming or 
starting any hypocholesterolemic agents during the formal 
POSCH trial, which ended on July 19, 1990. 
Patients were eligible for the POSCH trial if they were 
between 30 and 64 years of age and had survived a single 
myocardial infarction that was documented by serial electro- 
cardiographic and cardiac enzymatic hanges and that had 
occurred between 6and 60 months before the date of random- 
ization. After following the American Heart Association phase 
II diet for at least 6 weeks, patients were required to have 
a total plasma d,olesterol level of at least 5.69 retool/liter 
(220 rag/all) or a low density lipoprotein (LDL) cholesterol 
level of at least 3.62 mmol/liter (140 mg/dl) if their total plasma 
cholesterol levels were between 5.17 and 5.66 mmol/liter (200 
and 219 mg/dl). The POSCH trial was designed as a unifacto- 
rial intervention trial; therefore, most of the major confound- 
ing atherosclerosis r k factors, with the exception of cigarette 
smoking, were criteria for exclusion, hnmediately after com- 
pletion of the prerandomization coronary arteriogram, ran- 
domization was performed by the POSCH Coordinating Cen- 
ter. Control group patients were discharged from the hospital. 
Intervention group patients remained in the hospital and 
underwent partial ileal bypass. The partial ileal bypass proce- 
dure has been described in detail (2). Briefly, the operation 
involves bypass of either the distal 200 cm or the distal one 
third of the small intestine, whichever length is greater, with 
restoration of intestinal continuity by an end to side ileocecos- 
tomy. The risks and side effects of partial ileal bypass include 
diarrhea, kidney stones, gallstones and, like any abdominal 
surgical procedure, subsequent bowel obstruction (1) POSCH 
methods and procedures were approved by the institutional 
review committees of all four participating institutions, the 
grant peer review committee, a~,d the POSCH Data Monitor- 
ing Committee. The patients gave informed consent hrough- 
out the study. 
The average age of the patients at randomization was 51 
years. The mean interval between the qualifying myocardial 
infarction and entry into the trial was 2.2 years. The lipid and 
lipoproteJn changes in POSCH have previously been described 
(1,7-10). At 5 years, the intervention group, compared with the 
control group, had a, 23.3 _ 1.0% (mean +-_ SEM) lower total 
plasma cholesterol level (p < 0.0001), a 37.7 +-- i.2% lower 
LDL cholesterol level (p < 0.0001), a 4.3 +__ 1.8% higher high 
density lipopr6tein (HDL) cholesterol level (p = 0.02), an 
18.3 - 7.5% higher very low density lipoprotein cholesterol 
level (p = 0.02), a 19.8 +- 6.5% higher triglyceride l vel (p = 
0.003), a 37.8 - 2.8% higher ratio of HDL to total plasma 
cholesterol (p < 0.0001) and a 71.8 _+ 4.3% higher atio of HDL 
to LDL cholesterol (i 3 < 0.0001) (1). At 5 years, the intervention 
group had a significantly higher level of the HDL 2 subfraction 
(p < 0.0001) and of apolipoprotein A-I (p < 0.0001) and a 
significantly lower level of apolipoprotein B-100 (p < 0.0001) 
than the control group (1). Comparable ipid changes were found 
il: a subgroup analysis of the women in the POSCH trial (4). 
The clinical and arteriographic end point results up to the 
completion of the formal POSCH trial on July 19, 1990, with 
the number of events, the incidence rates, adjustments for 
baseline covariates, the 95% confidence intervals, and the p 
values have been reported (1,4,11). There was a 21.1% risk 
reduction for the primary end point of werall mortality (p = 
0.164), a 28% risk reduction for coronary heart disease mor- 
tality (p = 0.113) and a 36.1% risk reduction for overall 
mortality in a data-derived subgroup analysis of patients with a 
left ventricular ejection fraction ---50% (p = 0.052 by the 
Mantel-Haenszel test and p = 0.021 by the Gehan test). The 
combined end point of coronary heart disease death and 
confirmed nonfatal myocardial infarction was reduced by 35% 
(p < 0.0001), the most conclusive reduction of this end point in 
any lipid/atherosclerosis intervention trial. There was a signif- 
icant reduction in peripheral vascular disease incidence as 
measured by clinical (27.1%, p = 0.038) and Doppler ultra- 
sound (43.5%, p < 0.01) criteria. The incidence of coronary 
artery bypass grafting was decreased by 62.3% in the interven- 
tion group (p < 0.0001), and the total number of invasive 
cardiac procedures (including percutaneous transluminal cor- 
onary angioplasty) was 2.6 times greater in the control group. 
At each arteriographic follow-up interval (3 y, 5 y, 7 y and 
10 y), there was significantly ess arteriographic coronary artery 
disease progression i  the intervention group compared with 
the control group (p < 0.001). Furthermore, at both 5 years 
and 7 years, there was a significantly greater incidence of 
regression of arteriographic coronary artery disease in the 
intervention group (p < 0.01). The proportion of POSCH trial 
patients free of angiographicaUy assessed peripheral vascular 
disease was consistently greater in the intervention group 
compared with the control group, a difference that nearly 
achieved statistical significance after 10 years of follow-up (p = 
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0.09). Arteriographic follow-up of the POSCH population has 
ended. There were no statistically significant differences in the 
occurrences of cerebrovascular events or of cancers between 
the two groups. 
The first publication of the POSCH results, in October 
1990, consisted of an assessment of the data base of 838 
patients up to July 20, 1990 (follow-up of 7 to 14.8 y, mean 
9.7 y) (1). After final clinical visits in the fall of 1990, the 
POSCH population has been followed by annual detailed 
telephone interviews, in addition to the continuous reporting 
and confirmation of clinical events. This report is based on the 
patient data up to September 30, 1993, and therefore repre- 
sents a patient follow-up of 10.2 to 18 years (mean, 12.9 y). 
Acquisition and verification of follow.up data. All patients 
were followed up by scheduled telephone contacts every 1 to 3 
months and by annual clinical visits for the first 5 years after 
randomization and then at either 7 or 10 years after random- 
ization, depending on whether they were randomized after or 
before June 1, 1980. In October 1990, an annual extended 
telephone contact schedule was initiated for each patient, with 
the telephone contact occurring as close to the patient's 
randomization date as feasible. Clinical events (e.g., death, 
myocardial infarction) are reported by the patient or by the 
patient's family or physician, as they occur, with missed events 
ascertained uring the annual telephone contact. All major 
events are recorded and verified by obtaining hospital records 
and death certificates, as well as by discussions with the 
patient's physician. The cause of death is determined by the 
POSCH Mortality Review Committee based on a blinded 
review of all available records. To date, no patient has been 
lost to follow-up. 
Data analyses and statistics. For each of the clinical end 
points, the incidence rate (number of events/I,000 patients), 
the percent risk reduction in the intervention group, the 95% 
confidence interval and the p value were calculated. Confi- 
dence intervals and risk reductions were based on the propor- 
tion of events per group. In the life-table analyses, the date of 
randomization was used as the starting point. The Mantel- 
Haenszel statistic was used for comparisons of survival and 
events (12). All analyses were based on randomization assign- 
ment (intention to treat) whether or not the treatment was 
actually carried out. A two-sided p value <0.05 was used to 
define statistical significance. 
A Kaplan-Meier plot (13) was prepared for each clinical 
end point for the proportion of patients free of the event in 
both the control and the intervention groups up to September 
1993. To determine the disease-free intervals for the control 
and the intervention groups at 5 years and 10 years and the 
relative gain in freedom from an end point by the intervention 
group, the vertical 5- and 10-year intercepts of the control 
group and the intervention group curves were projected hori- 
zontally onto the ordinate. To determine disease-free intervals 
and the relative gain in years by the intervention group for a 
given end point, horizontal line intercepts of the control group 
and the intervention group curves, up to the approximate 
decile below which neither the control group nor the interven- 
tion group graph extended, were projected vertically onto the 
abscissa. For an overall mortality rate, 10% was chosen for 
analysis; for coronary heart disease mortality, the number of 
events and the flatness of the curves at 10% dictated the use of 
8% as the cutoff point. For the other end points, the propor- 
tion of patients without the event was calculated in live 
hundredths from 0.9 to the decile below which neither the 
control group nor the intervention group graph extended and 
was expressed as the reciprocal value, that is, 0.8 proportion of 
patients without an event is equivalent to a 20% incidence rate. 
To detelraine the standard errors of the estimates of disease- 
flee intervals and the intervention group advantage, we used the 
squared standard errors of the heights of the Kaplan-Meier 
curves and the squares of the slopes of the curves where the 
horizontal percentile lines intersect he curves. Because the 
Kaplan-Meier curves are actually step functions, thus having a 
zero slope almost everywhere but undefined at the step points, it 
is necessary to smooth the step functions. The smoothing method 
used is that of MathCad Version 4.0 (14). From these smoothed 
curves, the slopes were calculated at the points of intersection 
with the horizontal percentile lines. With these slopes, the stan- 
dard errors of the disease-free interval estimates were obtained. 
Specifically, they are the square roots of the squared standard 
errors of the Kaplan-Meier functions, each divided by their 
respective squared slopes, which are then added. Thus the 
standard error for the intervention group disease-free interval 
advantage stimate iscalculated according to the formula: 
SE = ~ - t  SE2: 
\l Slope12 Slope22. 
With the standard errors of the estimates, both hypothesis 
testing and confidence interval determinations can easily be 
performed. 
Results  
POSCH results update. Table I presents an update of the 
POSCH results through September 30, 1993, and gives for 
each clinical end point the number of events in the control 
group and the intervention group, the incidence i'ate for each 
event per 1,000 patients for the control group and the inter- 
vention group, the risk reduction in the intervention greup, the 
risk ratio, the 95% confidence interval for the risk ratio and the 
Mantel-Haenszel p value for the differences in proportions of 
patients ustaining the event between the control group and 
the intervention group. The statistical significance assessment 
for 11 of the 13 clinical end points has varied little since the 
original presentation f the POSCH trial data (1). For the end 
points of overall mortality and coronary heart disease mortal- 
ity, the greater numbeT .qf control group patients compared 
with surgery group patients experiencing these end points 
between 1990 and 1992 lowered the p value for overall 
mortality from 0.164 to 0.052 and the p value for coronary 
heart disease mortality from 0.113 to 0.058. However, by 
September 1993, there was a mild reversal in this trend, as 
shown in Table 1. 
354 BUCHWALD ET AL. JACC Vol. 26, No. 2 
POSCH DISEASE-FREE INTERVALS August 1995:351-7 
Table 1. POSCH Results up to September 30, 1993 
No. of Events No. of Events/1,0O0 Pts Risk 
Reduction i  
Control Interventioa Contro l  Intervention Intervention Risk p 
End Points Group Group Group Group Group (%) Ratio 95% CI Value 
Overall mortality 84 66 201 157 24.8 0.752 0.545-1.038 0.082 
CHD mortality 56 41 134 97 29.9 0301 0.469-1.049 0.083 
Overall mortality, ejection 53 32 127 76 40,6 0,594 0.383-0.921 0,019 
fraction ->50% 
CHD mortality and confirmed 136 88 326 209 40.3 0.597 0.456-0.781 <0.001 
nonfatal MI 
CHD mortality and confirmed 151 98 362 233 40.5 0.595 0.461-0.767 <0.00l 
and suspected nonfatal MI 
CrtD mortality, all MIs and 265 200 635 475 36.2 0.638 0.530-0.766 <0.001 
episodes of unstable angina 
Overall mortality and confirmed 160 110 384 261 37.1 0.629 0.493-0.802 <0.001 
nonfatal MI 
Overall mortality and confirmed 172 117 412 278 38.1 0.619 0.490-0.783 <0.001 
and suspected nonfatal MI 
Overall mortality, all MIs and 281 217 674 515 34.9 0.651 0.545-0378 <0.001 
episodes of unstable angina 
Peripheral vascular disease ly./ 86 60 206 143 34.7 0.653 0.469-0.908 0.011 
clinical criteria 
CABG 156 69 374 164 63.1 0.369 0.278-0.490 <0.001 
PTCA 48 30 115 71 42.3 0.577 0.366-0.911 0.017 
All CABG, PTCA and heart 183 96 439 228 56.4 0.436 0.340-0.558 <0.001 
transplantation procedures 
combined 
CABG = coronary artery bypass grafting; CHD = coronary heart disease; CI = confidence interval; MI = myocardial infarction; PTCA = percutaneous 
transluminal coronary angioplasty; Pts = patients. 
Disease-free intervals. The data for the 13 clinical end 
points are presented in Table 2 as 5- and 10-year disease-free 
interval assessments. This analysis a variation of the conven- 
tional risk ratio evaluation and presents the data in a fomaat 
similar to that employed in oncology trials. 
The overall disease-free intervals for the 13 clinical end 
points are presented in Table 3, which includes the occurrence 
rate, the determined time in years for the occurrence ofthat 
end point in the control group and in the intervention group, 
the years gained for the disease-free interval by the interven- 
tion group and the p value for that gain. 
Assessment of major POSCH clinical end points. The 
major clinical end points in the POSCH trial are overall 
mortality, coronary heart disease mortality, coronary heart 
disease mortality and confirmed nonfatal myocardial infarction 
and all coronary intervention procedures (bypass urgery, 
repeat bypass urgery, coronary angioplasty and heart rans- 
plantation). An overall mortality rate of 10% occurred at 6.7 
years in the control group and 9.4 years in the intervention 
group, for a gain in this disease-free interval of 2.7 years in the 
intervention group (p = 0.032). A coronary heart disease 
mortality rate of 8% occurred at 7.2 years in the control group 
and 11 years in the intervention group, for a gain in this 
disease-free interval of 3.8 years in the intervention group (p = 
0.046). Twenty percent of the patients demonstrated the 
combined end point of coronary heart disease mortality and 
confirmed nonfatal myocardial infarction at 5.9 years in the 
control group and 11.4 years in the intervention group, for a 
gain in this disease-free interval of 5.5 years in the intervention 
group (p < 0.001) (Fig. 1). Twenty-five percent of the patients 
uaderwent either coronary artery bypass urgery, coronary 
angioplasty or a heart ransplant at 5.4 years in the control 
group and 12.4 years in the intervention group, for a gain in 
this disease-free interval of 7 years in the intervention group 
(p < 0.001) (Fig. 2). 
Discuss ion  
POSCH overview. The POSCH trial has provided strong 
evidence, in a secondary intervention setting, for a reduction 
of subsequent coronary events by marked lipid modification. 
This conclusion issupported by the highly significant reduc- 
tion in the combined end point of coronary heart disease 
mortality and confirmed nonfatal myocardial infarction. The 
consistent significant reductions ofall end points, combined 
with overall mortality and coronary heart disease mortality, 
offer further confirmation of this finding, as do th~ marked 
reductions in incidence of coronary artery bypass surgery 
and coronary angioplasty. Regardless of the cost assump- 
tions made, calculation of the savings that would ensue from 
a >50% reduction i  interventional coronary procedures is 
formidable. Partial ileal bypass management itself is more 
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Table 2. Five- and 10-Year Disease-Free Intervals 
End Points Control 
Propoltion Without Evert (%) 
5-Year Interval 
Gain in 
Intervention 
Intervention Group (%) 
10-Year Interval 
Gain in 
p Intervention p 
Value Control Intervention Group (%) Value 
Overall mortality 92.3 94.5 2.2 
CHD mortality 94.9 95.7 0.8 
Overall mortality, ejection fraction 92.5 97.5 5.0 
->50% 
CHD mortality and confirmed 83.1 88.1 5.0 
nonfatal MI 
CHD mortality and confirmed and 81.4 86.5 5.1 
suspected nonfatal MI 
CHD mortality, all Mls and episodes 66.2 76.6 10.4 
of unstable angina 
Overall mortality and confirmed 80.7 87.2 6.5 
nonfatal MI 
Overall mortality and confirmed and 79.0 85.5 6.5 
suspected nonfatal MI 
Overall mortality, all Mls and 64.3 75.8 11.5 
episodes of unstable angina 
Peripheral vascular disease by 89.4 92.6 3.2 
clinical criteria 
CABG 80.0 90.9 10.9 
PTCA 97.5 99.0 1.5 
All CABG, PTCA and heart 77.7 89.9 12.2 
transplantation procedures 
combined 
0.197 85.4 89.1 3.7 0.109 
0.569 89.7 92.8 3.1 0.119 
0.006 86.3 91.8 5.5 0.035 
0.040 70.3 82.1 11.8 <0.001 
0.046 67.3 80.2 12.9 <0.001 
0.001 43.1 59.8 16.7 <0.001 
0.806 66.0 78.8 12.8 <0.001 
0.014 63.5 77.6 14.1 <0.001 
<0.001 41.2 57.7 16.5 <0.001 
0.092 83.0 88.0 5.0 0.036 
<0.001 62.2 87.6 25.4 <0.001 
0.093 91.3 95.7 4.4 0.012 
<0.001 56.2 83.0 26.8 <0.001 
Abbreviations a in Table 1. 
than cost effective in comparison to hypocholesterolemic 
drug therapy after approximately 7 years (151. Furthermore, 
POSCH gave evidence for iess peripheral vascular disease in 
the intervention group. The trial provided the largest and 
longest sequential assessment of coronary arteriograms to 
show less ather,~sclerosis progression and more atheroscle- 
rosis regression after lipid modification, and it gave sub- 
stance and statistical credence to the use of sequential 
coronary arteriography as a surrogate nd point for clinical 
events. The 1992 incidence levels for overall mortality 
'"~ = 0.052) and coronary heart ~z6.8% risk reduction, p 
disease mortality (34.1% risk reduction, p = 0.058) ap- 
'fable 3. Overall Disease-Free Intervals 
Occurcnce 
End Points Rate (%) 
Years Years Gained 
in Intervention p 
Control Intervention Group Value 
Overall mortality 
CHD mortality 
Overall mortality, ejection fraction ->50% 
CHD mortality and confirmed nonfatal Mt 
CHD mortality and confirmed and suspected nonfatal MI 
CHD mortality, all Mls and episodes of unstable angina 
Overall mortality and confirmed nonfatal MI 
Overall mortality and confirmed and suspected nonfatal MI 
Overall mortality, all Mls and episodes of unstable angina 
Peripheral vascular disease by clinical criteria 
CABG 
PTCA 
All CABG, PTCA and heart transplantation procedures 
combined 
10 6.7 9.4 2.7 0.032 
8 7.2 11.0 3.8 0.046 
10 7.1 11.7 4.6 0.003 
20 5.9 I 1.4 5.5 <0001 
20 5.4 10.6 5.2 <0.001 
50 8.2 13.2 5.1 <0.001 
25 6.6 I 1.6 4.9 <0.001 
25 6.1 11.i 5.0 <0.001 
55 8.9 13.4 4.6 <0.0(11 
15 8.7 12.7 3.9 0.004 
15 3.5 10.7 7.2 <0.001 
5 6.4 10.4 4.0 0.009 
25 5.4 12.4 7.0 <0.001 
Abbreviations a in "l-able 1. 
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Figure 1. Coronary heart disease mortality and confirmed nonfatal 
myocardial infarction life-table analysis illustrating horizontal line 
intercepts of incidence curves for the control group (dashed line, n = 
417) and the intervention group (solid line, n = 421) and vertical 
projections from intercept oints to the time axis. 
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Figure 2. Combined life-table analysis for all coronary artery bypass 
graft surgery, percutaneous transluminal coronary angioplasty and 
heart ransplantation procedures, illustrating horizontal line intercepts 
of incidence curves for the control group (dashed line, n = 417) and 
the intervention group (solid line, n = 421) and vertical projections 
from intercept oints to the time axis. 
proaehed statistical significance. It will be important o 
follow these end points over time. If statistical significance is
achieved ana maintained, POSCH may demonstrate r duc- 
tions in overall and coronary heart disease mortality within 
a single trial. 
No POSCH trial patient has been lost to follow-up. POSCH 
follow-up did not cease at the end of the trial but is ongoing. 
The annual telephone contacts with all POSCH trial patients 
and the exhaustive documentation f all cardiovascular events 
in these patients will continue to increase our knowledge of the 
extended benefits of lipid modification i  atherosclerosis treat- 
ment. 
Disease-free intervals. The primary purpose of this re- 
port is to present he POSCH data in a form unique to the 
presentation of coronary heart disease intervention trials 
and analogous to that employed by oncologists in discussing 
trial outcomes. Oncologists peak of "expected time" or 
"average time" to recurrence of disease. Restated, they 
speak of the anticipated time of remission or the disease- 
free interval. We believe that it would be useful to discuss 
cardiovascular disease vents (e.g., myocardial infarction) in 
a similar manner. 
Technically, the figure most easily obtainable from patient 
follow-up data is not the average time of remission but the 
median time of remission. The median time of remission can 
be obtai~led by following patients until 50% of them have had 
a recurrence of disease or event, not until all patients have had 
a recurrence. The medians, or 50th percentiles, for events or 
trial end points in POSCH are not available, as yet. We do, 
however, have other percentiles available, e.g., 10%, 20% and 
30%. The difference in years between the control group and 
the intervention group in achieving an end point is calculated 
from the Kaplan-Meier life-tables, as described. To provide for 
statistical examination of these data, standard errors need to 
be calculated employing the slopes of the Kaplan-Meier 
curves. Since a zero slope would lead to a confidence interval 
of infinite length, we were forced, at times, to use percentiles 
other than, but closest o, the nearest decile. 
If we accept the overwhelming evidence in support of 
lipid modification, we are warranted to interpret data from 
lipid/atherosclerosis intervention trials to the best advan- 
tage of patients with atherosclerosis. We have done this with 
respect o the analyses of the disease-free intervals in the 
POSCH trial. The hypothetical patient with a history of a 
single myocardial infarction can expect to have a 20% 
chance of an acute coronary event, expressed as coronary 
heart disease death or nonfatal myocardial infarction, at 5.9 
years without major lipid-lowering therapy or at 1!.4 years 
with major lipid-lowering therapy. Such a patient can expect 
to gain 7 years of freedom, at a 25% level of confidence, 
from a recommendation for coronary intervention manage- 
ment by electing marked lipid-lowering therapy. Such a 
patient has a 10% chance of death 2.7 years later (6.7 years 
without major lipid therapy vs. 9.4 years with major lipid 
therapy) and a chance of coronary heart disease death 3.8 
years later (7.2 years without major lipid therapy vs. 11 years 
with major lipid therapy) by undergoing marked total 
plasma cholesterol (>20%) and LDL cholesterol (>35%) 
lowering. 
Clinical implications. For the clinician, knowledge of an 
expected isease-free interval for specific cardiovascular 
events and for mortality is important, and the clinician has 
the right to ask for this information from the clinical trialist. 
The patient participating by previous consent in his or her 
therapy is also entitled to know the disease-free intervals he 
or she is likely to achieve by diet, drug or surgical manage- 
ment, as well as all of the side effects and complications 
inherent in the mode(s) of treatment elected. We would 
therefore ncourage the calculation of disease-free intervals 
from the study data of atherosclerosis intervention trials and 
the presentation of these data in the scientific literature. We 
preseated a method for obtaining disease-free intervals and 
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the difference in time of occurrence between control and 
intervention groups from Kaplan-Meier plots, as well as a 
method for testing the statistical sigt,ificance of these cal- 
culations. 
Consultants: David H. Blankenhorn, MD,* Linda-Cashin-Hemphill, MD
Jerome Cornfield, MA,* William L. Holmes, PhD,* Manford D. Morris, PhD. 
National Heart, Lung, and Blood Institute Project Officers: Thomas P. 
BlaszkowskL PhD, Lawrence M. Friedman, MD, Curt D. Furberg, MD, 
Jeffrey L. Probstfield, MD. 
Appendix 
Participating Investigators and Institutions for the 
POSCH Group 
Principal Investigators: Henry Buchwald, MD, PhD, Richard L. Varco, MD, 
PhD, Christian T. Campus, MD. 
Univers,:y of Minnesota Clinic, Minneapolis, Minnesota: Arthur S. Leon. 
MD, Jean ~;iadal, RN, MA, Rebecka A. Hagen, RN, MS. 
University of Arkansas Clinic, Little Rock, Arkansas: Gilbert S. Campbell, 
MD, PhD, Malcolm B. Pearce, MD, Joseph K. Bissett, MD, Me,edith R. 
Stuenkel, RN. 
Unive~.ity ofSoutl~ern California Clinic, Los Angeles, California: Albert E. 
Yellin, MD, W. Allan Edmi~ton, MD, Dorothy C. Fujii, Julie A. Hatch, RN. 
Lankenau Hospital, Philadelphia, Pennsylvania: Robert D. Smink, Jr., MD, 
Henry S. Sa~n, Jr., MD, Frederic J. Weber, MD, PhD, Helenc B. Brook% BS, 
Rebecca F. Carins, RN, MS, Margaret E. Trobovic, RN. 
Central Electrocardiographic Laboratary: Naip Tuna, MD, PhD, James N. 
Kamegis, MD, Phi), James E. Stevenson, MD, Regina Brykovsky, Mark A. Liassen. 
Central Lipid lahorntory: Jane C. Speech, MS. 
Central Arteriography/Radiology Laboratory: Kurt Amplatz, MD, Miguel E. 
Sanmarco, MD, Wilfredo R. Castaneda-Zuniga, MD, David W. Hunter, MD, 
Nancy P. Wehage, BS. 
Electrocardiographic Review Panel: Naip Tuna, MD, PhD, Chairman, 
Joseph K. Bissett, MD, W. Allan Edmiston, MD, James N. Kamegis, MD, PhD, 
Arthur S. Leon, MD, Malcolm B. Pearce, MD, l-tenry S. Sawin, Jr., MD, 
James E. Stevenson, MD. 
Arteriography Review Panel: Miguel E. Sanm,~rco, MD, Chairman, Kurt 
Amplatz, MD, Joseph K. Bissett, MD, Wilfredo R. Castaneda-Zuniga, MD  
W. Allan Edmiston, MD, David W. Hunter, MD, Malcolm B. Pearce, MD, 
Henry S. Sawin, Jr., MD, Frederic J. Weber, MD, PhD. 
Coordinating Center: John M. Long, EdD, John P. Matts, PhD, Laurie L. 
Fitch, MPH, James W. Johnson, MS, James R. Boen, PhD, Stanley E. Williams, 
BA, Phuong Nguyen, BA, James Vagasky. 
Administration: Betty J. Hansen, RN. 
Data Monitoring Committee: Thomas C. Chalmers, MD, Chairman, 
Jacob E. Bearman, PhD, Gerald R. Cooper, MD, PhD, Samuel W. Greenhouse, 
PhD, J. Ward Kennedy, MD, Paul Meier, PhD, Curtis L. Meinert, Phi3, 
Jeremiah Stamler, MD, D. Eugen~ Strandness, MD. 
Mortality Review Committee: J sse E. Edwards, MD, Original Chairman, 
Jack L. Titus, MD, PhD, Chairman, Lawrence S.C. Grittith, MD, Arthur J. Moss, 
MD, David Spain, MB. 
Policy and Data Monitoring Board: Antonio M. Gotto, Jr., MD, DPhil, 
Chairman, C. Morton Hawkins, ScD, James J. Leonard, MD, Floyd D. Loop, 
MD, Elliot Rapaport, MD, David L. Sylwester, Phi), Do'is Tulein, HA. 
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